

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Upadacitinib 45 mg extended-release (Rinvoq 45 mg ER)

Notes:

- Quantity Limits: Yes
- Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- *Per FDA approved dosing, upadacitinib 45 mg extended-release should only be used for 8 weeks (ulcerative colitis) or 12 weeks (Crohn's disease) as induction therapy. After the induction period, dose should be reduced to 15 mg or 30 mg once daily.

ULCERATIVE COLITIS:

Initiation (new start) criteria: Non-formulary **upadacitinib 45 mg extended-release (Rinvoq 45 mg ER)** will be covered on the prescription drug benefit for 8 weeks when the following criteria are met:

- Prescriber is a gastroenterologist and patient has a diagnosis of ulcerative colitis
- Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **upadacitinib 45 mg extended-release (Rinvoq 45 mg ER)** will be covered on the prescription drug benefit for 4 weeks when the following criteria are met:

- Prescriber is a gastroenterologist and patient has a diagnosis of ulcerative colitis
- Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
- Duration of treatment with upadacitinib 45 mg extended-release tablets will not exceed 8 weeks*

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Upadacitinib 45 mg extended-release (Rinvoq 45 mg ER)

CROHN'S DISEASE:

Initiation (new start) criteria: Non-formulary **upadacitinib 45 mg extended-release (Rinvoq 45 mg ER)** will be covered on the prescription drug benefit for 12 weeks when the following criteria are met:

- Prescriber is a gastroenterologist and patient has a diagnosis of Crohn's disease
- Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)

Criteria for *new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:* Non-formulary **upadacitinib 45 mg extended-release (Rinvoq 45 mg ER)** will be covered on the prescription drug benefit for up to 8 weeks when the following criteria are met:

- Prescriber is a gastroenterologist and patient has a diagnosis of Crohn's disease
- Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
- Duration of treatment with upadacitinib 45 mg extended-release tablets will not exceed 12 weeks*